Tirzepatide effectively provides good glycaemic control in diabetes patients undergoing hemodialysis: Study

Tirzepatide effectively provides good glycaemic control in diabetes patients undergoing hemodialysis suggests a study published in the Endocrinology, Diabetes & Metabolism.

Tirzepatide is an injectable peptide approved by the US Food and Drug Administration for the treatment of Type 2 diabetes (T2DM). Its weight-loss effect primarily targets fat reduction; however, such effect on patients with chronic kidney disease (CKD) undergoing haemodialysis (HD) has not been reported. Nine patients with chronic kidney disease undergoing haemodialysis received weekly tirzepatide doses (2.5-7.5 mg) once a week. Evaluations encompassed tirzepatide’s impact on dry weight (DW) and body composition assessed at baseline and study conclusion using bioelectrical impedance analysis. This longitudinal study included nine patients, with a median age of 53 years and median haemodialysis duration of 4 years. RESULTS: Tirzepatide treatment significantly decreased glycated albumin compared with the value at baseline (22.7 ± 5.4 vs. 18.3 ± 2.5%, p = 0.028, respectively). Significant reductions were observed in DW (-1.0 kg, p = 0.024) and body mass index (-0.6 kg/m2, p = 0.050) following tirzepatide administration. Total fat mass was also reduced, but not significantly (- 2.51% from baseline, p = 0.214). In contrast, skeletal muscle mass was not decreased (-1.02% from baseline, p = 0.722). No serious side effects other than nausea were observed during the study period. Tirzepatide effectively provides good glycaemic control in Type 2 diabetes patients undergoing haemodialysis, decreasing dry weight by reducing body fat mass without increasing frailty risk.

Reference:

Mima, Akira, and Yasuhiro Horii. “Tirzepatide Reduces Fat Mass and Provides Good Glycaemic Control in Type 2 Diabetes Patients Undergoing Haemodialysis: a Single-Centre Retrospective Study.” Endocrinology, Diabetes & Metabolism, vol. 7, no. 3, 2024, pp. e489.

Keywords:

Tirzepatide, effectively, provides, good, glycaemic, control, diabetes, patients, undergoing, hemodialysis, study, Mima, Akira, and Yasuhiro Horii

Powered by WPeMatico

FDA clears new OTC baby monitoring system

The US Food and Drug Administration (FDA) has cleared Stork new baby monitoring system intended for use with healthy babies 0 to 18 months of age. This is an over-the-counter (OTC) system which is indicated for spot-checking and continuous monitoring of oxygen saturation level (SpO2) and pulse rate (PR) during no motion, motion, and low perfusion conditions in infants and neonates 0 to 18 months of age weighing 6 to 30 lbs.

The over-the-counter (OTC) version of Stork utilizes the same Masimo pulse oximetry technology that monitors more than 10 million babies in hospitals every year1 and is used at 9 of the top 10 U.S. hospitals. The FDA-cleared OTC version of Masimo Stork monitors a baby’s key vitals data including oxygen saturation level (SpO2), pulse rate (PR), and skin temperature; crucially, Stork notifies caregivers with visual and audible alarms if a baby’s SpO2 or PR readings fall outside of preset ranges.

Stork leverages the same pulse oximetry technology that has been used on babies in the neonatal intensive care unit (NICU) for decades, helping to improve health outcomes for the youngest and most vulnerable patients. Known as Signal Extraction Technology®, or SET®, this technology has helped clinicians reduce the incidence of neonatal blindness from retinopathy of prematurity and has led to significant improvements in screening newborns for critical congenital heart disease.

“Bringing your new baby home from the hospital is exciting, but can be nerve- wracking-and it’s something I remember vividly from when my son was born and required at-home monitoring,” said Joe Kiani, Founder and CEO of Masimo. “I believe that by empowering parents and caregivers with the same Masimo pulse oximetry technology that hospitals have been using on babies for decades, we can help them feel more informed and confident when caring for their baby. It is particularly fitting that we received this clearance and are making this announcement as we celebrate the 35th anniversary of the company I founded with a mission to improve lives everywhere, especially those of the youngest and most fragile among us. Thirty-five years ago I envisioned Stork. I am so proud of our team for Stork-it is a culmination of science and design at its best.”

Stork bundles are currently available at major and specialty retailers nationwide and at masimo.com as a non-medical device for general health and wellness purposes. Alongside the FDA clearance, Masimo will make Stork’s new alarm features available to all existing and new Stork users through the Masimo Stork App, in an update scheduled to be released this summer. FDA-cleared OTC Stork bundles will be available for purchase online and at retailers this summer.

Masimo’s patented SET® sensor technology nests within the Stork boot, which is made from an ultra-soft, medical-grade silicone that conforms gently to the baby’s skin and is available in three sizes to ensure a perfect fit as the child grows. The sensor embedded in the boot is the product of meticulous engineering that harnesses decades of expertise in noninvasive monitoring to detect babies’ SpO2, PR, and skin temperature continuously, with unprecedented accuracy and dependability.

Masimo Stork has a sleek, minimalist design that fits seamlessly into any nursery and on the baby’s foot. The Stork Vitals+ bundle includes the boot with sensor that monitors baby’s skin temperature, PR, and SpO2, and a 2K Quad High-Definition (QHD) capable camera with technology supported by the TODA platform from Like Minded Labs. The camera hardware and software architecture are designed to leverage and be compatible with future edge AI-based features, which are in development. The first application of the edge AI technology will be identifying babies who have turned face down. For those who do not require streaming video, or detection via video of babies being face down, the Stork Vitals bundle replaces the camera with a hub, which connects the Stork vital signs sensor/boot to the Stork app, while still allowing parents to hear their baby. Stork also monitors the baby’s room conditions (ambient temperature and humidity).

Masimo Stork is 510(k) cleared for OTC use as a wearable device intended for the monitoring of multiple physiological parameters. Masimo Stork is indicated for spot-checking and continuous monitoring of SpO2 and PR during no motion, motion, and low perfusion conditions in infants and neonates who are 0 to 18 months of age and between 6 and 30 lbs. Masimo Stork OTC is also indicated for continuous skin temperature measurements of infants and neonates who are 0 to 18 months of age and between 6 and 30 lbs. Masimo Stork is indicated for use in home environments.

Masimo Stork can be used to supplement a caregiver’s decision to seek additional guidance for the care of an infant or neonate. It is not intended to provide notifications for every episode of the unexpected occurrences of elevated or depressed PR or low SpO2; rather, Masimo Stork is intended to provide a notification only when sufficient data are available for analysis.

Masimo Stork is not intended to replace the monitoring, diagnosis, or treatment provided by a physician or healthcare provider. Masimo Stork is not intended for use with infants and neonates previously diagnosed with cardiovascular or respiratory disease or conditions.

 

Powered by WPeMatico

Antibiotics use for acute sinusitis in children reduces treatment failures: Insights from meta-analysis

USA: Acute sinusitis is a common childhood ailment characterized by inflammation of the paranasal sinuses, often triggered by viral upper respiratory tract infections. While antibiotics have traditionally been prescribed for acute sinusitis, there has been growing debate regarding their efficacy and necessity, particularly in the context of rising concerns about antibiotic resistance. A recent meta-analysis sheds light on this contentious issue, offering valuable insights into the role of antibiotics in acute sinusitis management in children.

In the study published in the Pediatrics Journal, antibiotics significantly reduced treatment failure rate compared with placebo in children with clinically diagnosed acute sinusitis. However, given the favorable natural history of sinusitis, the results could also support close observation without immediate antibiotic treatment.

The meta-analysis provides valuable insights into the use of antibiotics for acute sinusitis in children, highlighting the importance of evidence-based decision-making and antibiotic stewardship in pediatric practice

In children, acute sinusitis is one of the leading causes of antibiotic prescriptions. No recent systematic reviews have examined antibiotic efficacy compared with placebo.

The meta-analysis, conducted by Shannon J. Conway, University of Pittsburgh School of Medicine, Children’s Hospital of Pittsburgh, Pittsburgh, Pennsylvania, and colleagues sought to determine if antibiotics are superior to placebo in the treatment of acute sinusitis in children.

For this purpose, Embase and Medline were searched from their origin to July 2023. Randomized placebo-controlled studies focusing on the treatment of acute sinusitis were considered. In all studies, symptoms were present for <4 weeks, and subjects were <18 years of age. Data extraction was done independently by two authors. Data was pooled primarily using fixed-effects models.

The researchers reported the following findings:

  • Analysis of 6 included studies showed that antibiotic treatment reduced treatment failure rate by 41% (with a risk ratio of 0.59) compared with placebo.
  • There was substantial heterogeneity between the studies (I2 = 69.7%), which decreased substantially when the 1 study with a high risk of bias was removed (I2 = 26.9%).
  • Children treated with antibiotics were 1.6 times more likely to have diarrhea than those who were not treated with antibiotics (risk ratio = 1.62).

In conclusion, antibiotics effectively reduce the symptoms of children with clinically diagnosed acute sinusitis. However, given the favorable natural history of the condition, the results could also be viewed as supporting close observation without immediate antibiotic treatment.

“Our results underscore the importance of shared decision-making with parents of children with acute sinusitis,” the researchers wrote.

The main limitation was that few studies were eligible for inclusion. The included studies differed in their methodology.

Reference:

Shannon J. Conway, Grace D. Mueller, Nader Shaikh; Antibiotics for Acute Sinusitis in Children: A Meta-Analysis. Pediatrics 2024; e2023064244. 10.1542/peds.2023-064244

Powered by WPeMatico

Rare case of Bell’s palsy and parsonage-turner syndrome following pneumococcal vaccination: a report

Parsonage-Turner syndrome (PTS), also known as brachial neuritis, is a rare self-limiting, idiopathic condition characterized by sudden onset upper extremity pain with associated weakness and muscle atrophy. There exists a growing association between the development of PTS and infection/vaccinations in recent years.

Bell palsy (BP) is an idiopathic disease process involving acute-onset unilateral acute facial paralysis resulting from edema and inflammation of the seventh cranial nerve. The etiology of BP is also largely unknown, but infectious processes, including viral reactivation and adverse vaccination reactions, have recently been documented. Although both PTS and BP are uncommon on their own, it is extremely rare for the 2 conditions to occur simultaneously.

Devin A. Maez et al presents a unique case of PTS and BP developing following the administration of the pneumococcal 20-valent conjugate vaccine.

A 66-year-old woman with no significant neurologic or musculoskeletal history presented to urgent care with low-grade fevers and diffuse myalgias 4 days after receiving the pneumococcal 20-valent conjugate vaccine from her primary care physician. Preliminary influenza and COVID-19 testing were negative, and she was advised to continue with at-home acetaminophen and nonsteroidal anti-inflammatory agents for symptomatic relief. She presented again to the emergency department 2 days later complaining of acute onset severe left shoulder pain with radiation to the neck and right upper quadrant (RUQ) postprandial pain.

An initial work-up included complete blood count, complete metabolic panel, lipase, and troponin, all of which were unremarkable. RUQ ultrasound was negative for choledocholithiasis or other acute pathology. Chest X-ray was negative for signs of acute infection, and electrocardiogram (ECG) was negative for myocardial infarction or coronary pathology. The patient’s left shoulder, deltoid region was noted to be erythematous with an area of firmness near her original injection site. The patient was administered 15 mg of intramuscular ketorolac with rapid improvement of her symptoms. Thus, her pain was attributed as likely musculoskeletal in nature. She was ultimately discharged without further work-up.

Two weeks later, the patient presented to the emergency department for a third time with acute onset right sided facial droop. After neurologic evaluation, she was diagnosed with BP in the setting of her recent vaccination and given a 7-day course of 1 g oral valacyclovir and 40 mg of oral prednisone. Her facial symptoms resolved with adequate treatment over the next several weeks.

Approximately 2 months later, the patient was evaluated in an outpatient orthopaedic sports medicine clinic for her persistent, severe pain and weakness in the left shoulder and arm, all of which had continued to steadily worsen since her vaccine was administered nearly 3 months prior. Her symptoms were now causing sleep difficulties and were significantly affecting her daily activities. At the time, she was still managing her symptoms with anti inflammatories and a home exercise program without relief.

A focused physical examination of the left upper extremity demonstrated full passive range of motion, with pain on active forward flexion of the shoulder joint and terminal range of motion. Left shoulder examination demonstrated positive Neer and Hawkins tests, indicating some degree of shoulder impingement. She had minimally decreased strength with resisted rotator cuff testing and was further noted to be neurovascularly intact distally. No apparent muscular atrophy was visible on examination.

Preliminary X-ray of the left shoulder was obtained and showed no major degenerative changes aside from mild acromioclavicular joint arthritis (Figs. 1 and 2). No fracture or dislocation was noted. A subsequent magnetic resonance imaging (MRI) of the left shoulder was ordered to evaluate for rotator cuff pathology and etiology of the disabling pain.

The MRI demonstrated moderate to marked edema involving the left infraspinatus and supraspinatus musculature and questionable minimal edema of the teres minor muscle without evidence of rotator cuff or deltoid muscular atrophy. The findings were most consistent with denervation changes. The MRI results were discussed with the patient in detail, which the provider diagnosed as most consistent with PTS in the setting of her recent vaccination and no other etiology. She was referred to formal physical therapy for further management and was advised to continue over-the-counter pain medications as needed. A cortisone injection was also offered, but the patient elected to defer during this visit. Her symptoms gradually improved with this treatment regimen over the next several weeks.

The authors concluded – “Both PTS and BP are acute denervation diseases affecting the brachial plexus and seventh cranial nerves, respectively that are often precipitated by an immune trigger, including vaccinations. PTS has not been reported in the setting of pneumococcal vaccination and is also rarely reported in conjunction with BP. Thus, it is imperative to recognize PTS-like and BP-like symptoms and administer adequate treatment to obtain the best possible patient outcomes. However, it is also imperative to note that vaccinations themselves, including their own distinct components, may not be the sole cause of these disease processes. Further research is needed to determine the sequelae of PTS and BP to provide safe and accurate recommendations for future patient care.”

Further reading:

BELL PALSY AND PARSONAGE-TURNER SYNDROME FOLLOWING PNEUMOCOCCAL VACCINATION: A CASE REPORT

Devin A. Maez et al

JBJS JOPA 2024; 12(1): e23.00024

http://dx.doi.org/10.2106/JBJS.JOPA.23.00024

Powered by WPeMatico

Home Self monitoring of BP and dose titration of drugs may improve long term BP control: JAMA

Researchers in a recent study have found that patient empowerment through self-management strategies can be effective in controlling chronic diseases like diabetes, but its application in managing hypertension has been limited. Researchers have long recognized the importance of patient involvement in managing chronic diseases as a means to improve treatment outcomes and overall health. This study was published in JAMA Network Open by Martínez-Ibáñez P. and colleagues.

While strategies such as pharmacologic self-management have been widely used for conditions like diabetes, their application in hypertension management has been relatively limited. Hypertension, a major risk factor for cardiovascular diseases, requires effective long-term management to reduce associated morbidity and mortality. However, despite the availability of pharmacological treatments, many patients struggle to achieve and maintain target blood pressure levels.

The ADAMPA study sought to address this gap by investigating the effectiveness of a self-management approach for hypertension control. Conducted in Valencia, Spain, the study enrolled patients aged 40 or older with poorly controlled hypertension, as evidenced by elevated systolic and/or diastolic blood pressure levels. Participants were randomized into two groups: one receiving standard care and the other receiving individualized self-management instructions, including self-monitoring of blood pressure and self-titration of antihypertensive medication.

The key findings of the study were:

  • Out of the 312 patients initially enrolled in the main trial, data on blood pressure measurements at the 24-month mark were available for 219 patients, with 111 in the intervention group and 108 in the control group.

  • The average age of the participants was 64.3 years, with a standard deviation of 10.1 years.

  • Among them, 120 patients, accounting for 54.8% of the cohort, were female.

  • The mean systolic blood pressure (SBP) at baseline was 155.6 mm Hg, with a standard deviation of 13.1 mm Hg, while the mean diastolic blood pressure (DBP) was 90.8 mm Hg, with a standard deviation of 7.7 mm Hg.

  • The median follow-up duration was 23.8 months, with an interquartile range (IQR) of 19.8 to 24.5 months.

  • At the end of the follow-up period, the adjusted mean difference (AMD) in SBP between the intervention and control groups was -3.4 mm Hg, with a 95% confidence interval (CI) ranging from -4.7 to -2.1 mm Hg (P < .001).

  • Similarly, the AMD in DBP was -2.5 mm Hg, with a 95% CI ranging from -3.5 to -1.6 mm Hg (P < .001).

  • Subgroup analysis for the primary outcome yielded consistent results across different patient characteristics, confirming the robustness of the main findings.

  • Additionally, sensitivity analyses further supported the reliability of the study’s results.

The implications of these findings are significant for both patients and healthcare providers. By empowering patients to take an active role in managing their hypertension, self-management interventions offer a promising avenue for improving treatment outcomes and reducing the risk of cardiovascular events. Importantly, the study demonstrated that self-monitoring of blood pressure and medication adjustment can be effectively implemented in primary care settings without increasing healthcare utilization or adverse events. This suggests that self-management interventions are not only clinically effective but also feasible and safe for routine clinical practice.

In conclusion, the ADAMPA study provides compelling evidence supporting the long-term effectiveness of self-management interventions for hypertension control. By integrating self-monitoring of blood pressure and self-titration of medication into routine care, healthcare providers can empower patients to actively participate in their treatment and improve their overall health outcomes.

Reference:

Martínez-Ibáñez, P., Marco-Moreno, I., García-Sempere, A., Peiró, S., Martínez-Ibáñez, L., Barreira-Franch, I., Bellot-Pujalte, L., Avelino-Hidalgo, E., Escrig-Veses, M., Bóveda-García, M., Calleja-del-Ser, M., Robles-Cabaniñas, C., Hurtado, I., Rodríguez-Bernal, C. L., Giménez-Loreiro, M., Sanfélix-Gimeno, G., Sanfélix-Genovés, J., Abad Carrasco, J., Agudo Escagüés, M. V., … ADAMPA Research Group. (2024). Long-term effect of home Blood Pressure self-monitoring plus medication self-titration for patients with hypertension: A secondary analysis of the ADAMPA randomized clinical trial. JAMA Network Open, 7(5), e2410063. https://doi.org/10.1001/jamanetworkopen.2024.10063

Powered by WPeMatico

Vitamin D levels associated with enhanced immune response against hepatitis B virus: Study

A recent study by Catharina Gerhards and colleagues looked in depth into the intricate relationship between vitamin D levels and immune response in patients with chronic hepatitis B (CHB) and chronic hepatitis C (CHC). The key findings of this study were published in the recent edition of Nutrition journal.

This study was conducted from January 1, 2013 to February 1, 2023 and highlighted on how vitamin D influences the innate and adaptive immune parameters which are crucial for managing these viral infections. The findings of the study offer critical insights into the immune dynamics of CHB and CHC patients. Hepatitis B virus (HBV) serological markers, complements and T lymphocyte subsets were analyzed from laboratory data including serum vitamin D levels that uncovered compelling evidence.

Among the key findings, this study observed a significant reduction in the percentage of CD4+ T lymphocytes and the CD4+/CD8+ ratio in both CHB and CHC patients when compared to the control group. The percentage of CD8+ cells showed an increase in this patient group. Also, a substantial decrease in vitamin D levels was observed specifically in CHB patients.

Further analysis revealed a notable correlation between vitamin D levels and various immune parameters. In CHB patients, vitamin D deficiency expressed a moderate negative influence on CD8 cell count and was associated with decreased antibody production. The positive ratio of HBV DNA and HBsAg decreased with increasing serum vitamin D levels.

The study highlighted the role of vitamin D as a potential modulator of immune function beyond CD8+ and CD4+ cells and extended to CD19+ cells. The study observed an intriguing negative relationship between vitamin D and complement C3 levels that indicated a need for further investigation.

The implications of these findings highlight that maintaining sufficient levels of vitamin D may hold the key to a more robust immune response against the chronic hepatitis viruses and can potentially lead to sustained virological response. In conclusion, this comprehensive study underlines the multifaceted role of vitamin D in shaping immune responses in chronic hepatitis patients. Unraveling these complexities can help to pave the way for novel therapeutic interventions and personalized treatment strategies tailored to optimize immune function and effectively manage these persistent viral infections.

Source:

Gerhards, C., Teufel, A., Gerigk, M., French, M., Antoni, C., Ebert, M., Neumaier, M., & Evliyaoglu, O. (2024). Potential role of Vitamin D in immune response in patients with viral hepatitis. In Nutrition (Vol. 124, p. 112447). Elsevier BV. https://doi.org/10.1016/j.nut.2024.112447

Powered by WPeMatico

Prophylactic wound irrigation with antiseptic solutions may reduce surgical site infections: JAMA

Surgical site infections (SSIs) remain a significant concern following surgeries by leading to complications, increased mortality rates and economic burdens. A recent comprehensive study published in the recent issue of Journal of American Medical Association highlights the effective preventive measures in the field of intraoperative wound irrigation.

This study rigorously examined randomized clinical trials and compared various types of prophylactic intraoperative incisional wound irrigation methods for their effectiveness in preventing SSIs across different surgical procedures. The study analyzed data from PubMed, Embase, CENTRAL and CINAHL databases up until June 12, 2023. Out of 1587 articles reviewed, 41 RCTs were included which encompassed a total of 17,188 patients and 1328 reported SSIs.

The findings revealed strong evidence that support the use of antiseptic solutions for intraoperative wound irrigation. When compared to no irrigation, the antiseptic solutions demonstrated a significant reduction in SSIs with a relative risk (RR) of 0.60 (95% CI, 0.44-0.81) and this was backed by a high level of certainty.

Similarly, antibiotic solutions expressed positive outcomes in reducing the risk of SSIs though with a lower level of certainty (RR 0.46; 95% CI, 0.29-0.73). Caution is imperative due to concerns regarding global antimicrobial resistance that prompts advise against routine use of antibiotic wound irrigation. The saline irrigation failed to show a statistically significant difference when compared to no irrigation, with a moderate level of certainty (RR 0.83; 95% CI, 0.63-1.09).

The benefits of these findings are profound for healthcare professionals and policymakers. Thereby, by implementing antiseptic solutions for intraoperative wound irrigation, hospitals and surgical teams can potentially reduce the occurrence of SSIs clinicians can enhance patient outcomes and reducing healthcare costs.

The study emphasized the importance of evidence-based practices in surgical settings. The findings underline the effectiveness of antiseptic solutions in preventing SSIs. This could urge caution regarding the use of antibiotic solutions after considering the possible threat of antimicrobial resistance. Overall, this study provides valuable inputs for improving patient care and highlights the ongoing need for judicious antimicrobial stewardship in healthcare settings.

Reference:

Groenen, H., Bontekoning, N., Jalalzadeh, H., Buis, D. R., Dreissen, Y. E. M., Goosen, J. H. M., Graveland, H., Griekspoor, M., IJpma, F. F. A., van der Laan, M. J., Schaad, R. R., Segers, P., van der Zwet, W. C., Orsini, R. G., Eskes, A. M., Wolfhagen, N., de Jonge, S. W., & Boermeester, M. A. (2024). Incisional Wound Irrigation for the Prevention of Surgical Site Infection. In JAMA Surgery. American Medical Association (AMA). https://doi.org/10.1001/jamasurg.2024.0775

Powered by WPeMatico

COVID-19 vaccine can help people with heart failure live longer, reveals study

Heart failure patients who are vaccinated against COVID-19 have an 82% greater likelihood of living longer than those who are not vaccinated, according to research presented today at Heart Failure 2024, a scientific congress of the European Society of Cardiology (ESC). Heart Failure is a life-threatening syndrome affecting more than 64 million people worldwide.

“Patients with heart failure should be vaccinated against COVID-19 to protect their health,” said study author Dr. Kyeong-Hyeon Chun of the National Health Insurance Service Ilsan Hospital, Goyang, Republic of Korea. “In this large study of patients with heart failure, COVID-19 vaccination was associated with a lower likelihood of contracting the infection, being admitted to hospital because of heart failure, or dying from any cause during a six-month period compared with remaining unvaccinated.”

Previous studies have shown the safety of COVID-19 vaccination in patients with cardiovascular diseases including heart failure, and that COVID-19 outcomes are worse in patients with heart failure compared to those without heart failure. However, there has been little research on how vaccines work specifically in patients with heart failure. This nationwide, retrospective study examined the prognosis of heart failure patients according to COVID-19 vaccination status.

This study used the Korean National Health Insurance Service database, which covers nearly all residents of the Republic of Korea, to obtain information on vaccinations and clinical outcomes. Participants who received two or more doses of COVID-19 vaccine were defined as “vaccinated”, and those who were not vaccinated or had received just one dose were defined as “unvaccinated”.

The study included 651,127 patients aged 18 years or older with heart failure. The average age was 69.5 years and 50% were women. Of the total study population, 538,434 (83%) were defined as vaccinated and 112,693 (17%) as unvaccinated. To control for factors that could influence the relationship between vaccination status and outcomes, the researchers performed 1:1 matching of vaccinated and unvaccinated patients according to age, sex, other health conditions (e.g. high blood pressure, diabetes, high cholesterol, etc.), income, and region of residence. This resulted in 73,559 vaccinated patients and 73,559 unvaccinated patients for the comparative analyses.

The median follow-up was six months. Vaccination was associated with an 82% lower risk of all-cause mortality, 47% lower risk of hospitalisation for heart failure, and 13% reduced risk of COVID-19 infection compared with no vaccination. Regarding cardiovascular complications, vaccination was associated with significantly lower risks of stroke, heart attack, myocarditis/pericarditis, and venous thromboembolism compared to no vaccination.

Dr. Chun said: “This was the first analysis of COVID-19 vaccine effectiveness in a large population of heart failure patients, and the first to show a clear benefit from vaccination. The study provides strong evidence to support vaccination in patients with heart failure. However, this evidence may not be applicable to all patients with heart failure, and the risks of vaccination should be considered in patients with unstable conditions.”

Powered by WPeMatico

Novel Anesthetic Patch Reduces Pain from Dental Injections in Children, reveals study

Researchers have found that a novel experimental anesthetic patch significantly reduces pain from local anesthetic injections during dental procedures in children. This study examined the tolerability and clinical efficacy of the new formulation patch, comparing it with an experimental gel and a placebo gel to assess their impact on pain control during local anesthetic injections in pediatric patients. The study was published in the Journal of Clinical Medicine by Gianmaria Fabrizio Ferrazzano and colleagues.

One of the main causes of fear and anxiety during dental sessions, particularly in children, is the injection of local anesthetics. To address this, topical anesthetics can be applied to minimize discomfort. This study aimed to evaluate the pain-reducing effects of an experimental anesthetic patch, previously tested in gel form, to better manage pain during dental injections.

The study involved 150 children, aged 4 to 9 years, and utilized a split-mouth procedure to test three different pre-anesthesia methods: a placebo gel, experimental gel, and experimental patch. Each method was used within a week of each other. Injection pain was measured using the Wong-Baker Faces Pain Rating Scale (WBFPRS) and the Face, Legs, Activity, Cry, Consolability (FLACC) scale. Caregivers’ satisfaction was also recorded. Data were analyzed using one-way ANOVA-RM, Wilcoxon-Mann-Whitney, Mann-Whitney U, and χ2 tests.

The key findings of the study were as follows:

  • The experimental patch was associated with significantly lower pain ratings in children during local anesthetic injections, as assessed by both the WBFPRS and FLACC scales.

  • In contrast, significantly higher pain ratings were observed with the placebo gel.

  • Patients’ caregivers reported greater satisfaction with the use of the experimental patch, indicating their preference for this method.

The results suggest that the novel experimental anesthetic patch is a promising option for reducing pain during dental procedures in children. The patch showed superior efficacy compared to the placebo gel and experimental gel, providing an effective method for pain management without any reported local or systemic side effects.

The study concludes that the use of the experimental anesthetic patch is an effective strategy for minimizing pain during local anesthetic injections in children, both subjectively and objectively. The patch is well-tolerated and improves the overall dental experience for pediatric patients, suggesting its potential for broader use in pediatric dentistry.

Reference:

Ferrazzano, G. F., Di Fabio, G., Caruso, S., Gatto, R., Goyal, V., & Caruso, S. (2024). Clinical efficacy and tolerability of a new experimental mucoadhesive patch for topical anesthesia of oral mucosa in pediatric dentistry. Journal of Clinical Medicine, 13(6), 1558. https://doi.org/10.3390/jcm13061558

Powered by WPeMatico

Higher number of biologics required for control of coexisting PsA and atopic dermatitis: Study

A recent study published in the Journal of Personalized Medicine observed new insights regarding the treatment of psoriatic arthritis (PsA) and its potential association with atopic dermatitis (AD). The study illuminates the effectiveness of biologic therapy in patients with PsA who also suffer from AD by providing crucial information for clinicians and patients alike.

The study analyzed data from a total of 64 patients with PsA who were undergoing treatment with various biologic agents over a period of up to 10 years. Among the key findings was the revelation that atopic diseases, including AD that was prevalent in approximately one-third of the cases studied. The incidence of AD was higher when compared to other atopic conditions such as atopic rhinitis and allergic asthma. Also, this study identified specific patterns of AD among PsA patients including chronic prurigo, chronic lichen simplex and eczemas.

The study highlighted the late onset of skin atopy among PsA patients with concomitant AD that occurred in their adult life. This finding underlines the importance of monitoring and addressing atopic conditions in PsA patients when selecting the most suitable biologic therapy. This study investigated the impact of biologic treatments, including TNF inhibitors and IL-17 inhibitor secukinumab on atopy and PsA. This found that long-term treatment with TNF inhibitors did not alter the course of atopy. The study also revealed that AD associated with psoriatic lesions did not respond uniformly to different anti-TNF agents.

The findings have significant implications for the management of PsA which suggests that atopy should be considered when selecting biologic agents for treatment. With the emergence of newer therapeutic options such as Janus kinase inhibitors (JAKinibs) which have shown efficacy in treating atopic dermatitis and asthma, the area of PsA treatment is continuously evolving.

This research highlighted a high rate of non-responders to biologic therapy among PsA patients with atopy by illuminating the need for better strategies to achieve optimal disease control. Further investigation in larger patient cohorts is imperative to validate these findings and refine treatment strategies. By deepening the understanding of the complex interplay between PsA and atopic disorders, the future of treatment holds promise for improved outcomes and quality of life for patients.

Source:

Strugariu, G., Pomîrleanu, C., Russu, M., Popescu, A., Petrariu, L. A., Ancuta, E., Chirieac, R., Temelie-Olinici, D., & Ancuța, C. (2024). Long-Term Outcomes of Patients with Biologically Treated Psoriatic Arthritis and Atopic Dermatitis—A Single-Center Experience. In Journal of Personalized Medicine (Vol. 14, Issue 4, p. 427). MDPI AG. https://doi.org/10.3390/jpm14040427

Powered by WPeMatico